The treatment of TGF-β in cancer cells results in the genetic alteration of important genes through transcriptional regulation, primarily targeting TGFB1 and TGFB3, which are repressed by c-Myc and Oct4/Klf4, respectively [3]. This evidence concerns the gene TGFB1 and cancer.